TCDA · Tricida, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| R&D | $115.36M | $148.42M | $133.03M | $21.82M |
| SG&A | $37.59M | $102.98M | $45.80M | $5.36M |
| Total Operating Expenses | $152.95M | $251.40M | $178.82M | $27.18M |
| D&A | $442.0K | $897.0K | $757.0K | $424.0K |
| Operating Income | ($152.95M) | ($251.40M) | ($178.82M) | ($27.18M) |
| Interest Expense | $17.60M | $18.41M | $5.74M | $0 |
| Income Tax | $0 | $0 | $0 | - |
| Net Income | ($176.57M) | ($264.79M) | ($176.81M) | ($28.65M) |
| EPS - Basic | ($5.29) | - | - | - |
| EPS - Diluted | ($5.29) | - | - | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|
| Cash & Equivalents | $21.11M | $137.86M | $18.57M | $37.17M |
| Accounts Receivable | - | - | - | - |
| Inventory | - | - | - | - |
| Accounts Payable | $10.02M | $3.51M | $5.91M | $8.46M |
| Current Assets | $145.54M | $314.01M | $312.74M | $244.35M |
| Total Assets | $168.51M | $351.69M | $371.83M | $247.85M |
| Current Liabilities | $29.48M | $34.26M | $39.76M | $14.80M |
| Long-term Debt | $0 | $76.64M | $58.37M | $0 |
| Total Liabilities | $168.29M | $242.81M | $107.94M | $53.32M |
| Stockholders' Equity | $218.0K | $108.87M | $263.88M | ($19.26M) |
| Retained Earnings | ($810.36M) | ($633.80M) | ($369.01M) | ($192.19M) |
Cash Flow
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|
| Operating Cash Flow | ($140.06M) | ($231.19M) | ($129.59M) | ($23.11M) |
| Investing Cash Flow | $64.22M | $140.28M | ($127.50M) | ($20.28M) |
| Financing Cash Flow | ($40.91M) | $210.19M | $238.49M | $42.97M |
| CapEx | $99.0K | $1.60M | $1.42M | $249.0K |
| Free Cash Flow | ($140.16M) | ($232.79M) | ($131.01M) | ($23.36M) |
Ratios
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|
| Profitability | ||||
| Gross margin | - | - | - | - |
| Operating margin | - | - | - | - |
| EBITDA margin | - | - | - | - |
| Net margin | - | - | - | - |
| Free cash flow margin | - | - | - | - |
| FCF / Net income | 0.79 | 0.88 | 0.74 | 0.82 |
| R&D / Revenue | - | - | - | - |
| SG&A / Revenue | - | - | - | - |
| Effective tax rate | - | - | - | - |
| Return on assets | -104.8% | -75.3% | -47.6% | -11.6% |
| Return on equity | -80993.6% | -243.2% | -67.0% | 148.8% |
| Return on invested capital | -55428.3% | -107.1% | -43.8% | - |
| Liquidity | ||||
| Current ratio | 4.94 | 9.17 | 7.87 | 16.51 |
| Quick ratio | 4.94 | 9.17 | 7.87 | 16.51 |
| Cash ratio | 0.72 | 4.02 | 0.47 | 2.51 |
| Leverage | ||||
| Debt / Equity | 0.00 | 0.70 | 0.22 | 0.00 |
| Debt / Assets | 0.00 | 0.22 | 0.16 | 0.00 |
| Debt / EBITDA | - | - | - | - |
| Interest coverage | -8.7x | -13.7x | -31.1x | - |
| Equity multiplier | 772.96 | 3.23 | 1.41 | -12.87 |
| Liabilities / Assets | 1.00 | 0.69 | 0.29 | 0.22 |
| Efficiency | ||||
| Asset turnover | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days inventory outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Cash conversion cycle | - | - | - | - |
| Valuation | ||||
| P / E | - | - | - | - |
| P / B | - | - | - | - |
| P / S | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| Growth | ||||
| Revenue growth (YoY) | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - |
| Operating income growth (YoY) | 39.2% | -40.6% | -557.9% | - |
| Net income growth (YoY) | 33.3% | -49.8% | -517.1% | - |
| EPS growth (YoY) | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - |
| FCF growth (YoY) | 39.8% | -77.7% | -460.7% | - |
| FCF CAGR (5y) | - | - | - | - |
| Book value growth (YoY) | -99.8% | -58.7% | - | - |
Stability scores
Piotroski F-score
FY 2021 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Tricida against the 5 most active filers in the same SIC group.